Sir,

Orthopedic surgeons commonly encounter cases of shoulder pain in their clinical practice, differential diagnosis of which includes, but is not limited to, septic arthritis. Usually perceived as 'benign', shoulder pain may be a harbinger of a serious underlying disorder including hematological malignancies. Jain et al. recently reported a case of chronic myeloid leukemia (CML) presenting as shoulder pain mimicking septic arthritis, and later diagnosed as myeloid sarcoma (MS) \[[@CR1]\]. MS represents an extramedullary accumulation of immature cells of granulocytic series and occurs most commonly in the setting of acute myeloid leukemia (AML), where its incidence is 2--8 %, occurring after (50 %), prior to diagnosis (25 %) or concurrently (15--35 %) with AML and may rarely be a first site of AML relapse. Diagnosis requires fine needle aspiration (FNA) and immunohistochemistry (MS being positive for myeloperoxidase) \[[@CR1]\]. Although bone and periosteum are amongst the commonest sites of MS, joint involvement is extremely rare and results from tumor invasion of the cortex and medulla resulting into a soft tissue mass \[[@CR3]\]. Considering the shoulder as an important though rare site of MS, we reviewed all cases of MS in the English literature involving the shoulder. A brief review of all cases of shoulder MS, including their clinical/radiological findings, treatment and outcome is presented in Table [1](#Tab1){ref-type="table"} \[[@CR1]--[@CR6]\]. Amongst six cases of shoulder MS, CML was the commonest underlying etiology, and in one of them MS was an initial presentation of CML. Males in their fourth decade were most commonly affected. Pain and mass in the shoulder were the commonest presenting complaints. Examination could identify splenomegaly (two cases) and axillary lymphadenopathy (one case), and MRI could identify a soft tissue mass (five cases) with or without an associated lytic lesion. From an orthopedic view point, septic arthritis was the commonest primary diagnosis. All the cases of CML received tyrosine kinase inhibitors, and three of them also received an additional systemic chemo-radiotherapy. Prognosis of shoulder MS is guarded and long term survival is unreported. Though MS is uncommon in CML, myelodysplastic syndrome and other myeloproliferative neoplasms, our literature review identified CML as the leading diagnosis in cases of MS of the shoulder. Considering its rarity, no definite treatment guidelines are available. Although systemic chemotherapy followed by allogeneic stem cell transplantation clearly offers a survival advantage in cases of MS, lack of matched sibling/unrelated donors and financial costs are real concerns in developing countries like India, where combined chemo-radiotherapy holds promise as the best form of 'palliation' due to lack of its survival benefits and the poorer prognosis of such cases \[[@CR1]\]. We conclude that, although septic arthritis is the commonest entity producing shoulder pain and swelling, presence of an associated lymphadenopathy, splenomegaly, soft tissue component with/without lytic lesion on MRI, peripheral leucocytosis with immature granulocytes/blasts, and absence of response to antibiotics should prompt an orthopedic surgeon to seek a hematology consultation maintaining a high index of suspicion for MS. Hematologists should henceforth realize the urgent need for FNA, and the importance of performing immunohistochemistry (IHC) in cases of septic arthritis with the above features being referred from the orthopedic side for timely and accurate diagnosis and treatment.Table 1Review of cases of shoulder myeloid sarcoma with clinical details, treatment given, and outcomeStudy no.AgeSexAuthorYearClinical presentationTime of presentation with shoulder sarcomaAdditional findingsImaging featuresSystemic involvementUnderlying diagnosisMolecular/cytogenetic abnormalitiesTreatment givenOutcome1.35MLevy et al. \[[@CR2]\]2014Right posterior shoulder painInitial presentation at diagnosisFirm mass at the back, axillary lymphadenopathyLytic lesion in inferior angle of scapula2 % blasts in periphery (CML-CP)CMLBCR-ABL1 (p210) rearrangementDasatinib followed by allogeneic SCTNot reported2.38MUpadhyay et al. \[[@CR3]\]2014Right shoulder painDiagnosed case of CML since 2009, on hydroxyurea for last 2 yearsSwelling over anterolateral aspect of right proximal arm, splenomegalySoft tissue mass lesion involving proximal part of\
right humerus with cortical breaks in the humeral head and\
neck completely encasing and infiltrating itCML-CPCMLNot availableSystemic chemotherapy and RTDied 6 months after diagnosis3.39MCozzi et al. \[[@CR4]\]2004Incidentally found to have myeloid sarcoma following a fracture after accidentDiagnosed as CML in 1989, received interferon, hydroxyurea and imatinibPain in left shoulderProximal humerus osteolytic lesion\
associated with extensive substitutive tissueBone marrow in CPCMLNot availableImatinib +dexamethasone + cytarabine followed by local RTDied due to mycotic pulmonary infection4.40MAlkubaidan et al. \[[@CR5]\]2007Painful swelling of left shoulder 1 year after Allo-SCTDiagnosed as SDS in teenage years, on pancreatic enzyme supplementation, with history of MDS, and underwent Allo-SCT 1 year backAvulsion fracture of greater tubercleSoft tissue mass circumferentially engulfing\
the proximal humerus, the rotator cuff and the long head\
of biceps tendonNAShwachman-Diamond syndrome\
(SDS)NANANA5.13MLincopan et al. \[[@CR6]\]2011Mass in right shoulderInitial presentationMass in inner thigh, rib cage, middle-posterior mediastinumSoft issue masses in the sub-dermal regionNot presentIsolated MSTrisomy 11NANA635FJain et al. \[[@CR1]\]2016Pain and swelling of left shoulderDiagnosed as CML-CP in 2004 (on Imatinib 400 mg OD), progressed to AP in 2014 (imatinib 600 mg) and had left shoulder pain in 2015Redness and induration of left shoulder, splenomegalyMRI of the left shoulder showing an ill-defined\
heterogeneously enhancing\
lesion involving the muscles\
around the shoulder and\
infiltrating into clavicleCML-CP (peripheral blood and Bone marrow)CMLBCR-ABL (H396R mutation in kinase domain)High dose imatinib, hydroxyurea, low dose cytarabine and local radiotherapy\
(RT)NA*CML* Chronic myeloid leukemia, *CP* chronic phase, *AP* accelerated phase, *SCT* stem cell transplantation, *NA* not available, *RT* radiotherapy
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